Anticancer Drug Resistance Advances in Molecular and Clinical Research / edited by Lori J. Goldstein, Robert F. Ozols.

Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomeno...

Full description

Saved in:
Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Goldstein, Lori J. (Editor), Ozols, Robert F. (Editor)
Format: eBook
Language:English
Published: New York, NY : Springer US : Imprint: Springer, 1994.
Edition:1st ed. 1994.
Series:Cancer Treatment and Research, 73
Springer eBook Collection.
Subjects:
Online Access:Click to view e-book
Holy Cross Note:Loaded electronically.
Electronic access restricted to members of the Holy Cross Community.

MARC

LEADER 00000nam a22000005i 4500
001 b3211004
003 MWH
005 20191029022840.0
007 cr nn 008mamaa
008 121227s1994 xxu| s |||| 0|eng d
020 |a 9781461526322 
024 7 |a 10.1007/978-1-4615-2632-2  |2 doi 
035 |a (DE-He213)978-1-4615-2632-2 
050 4 |a E-Book 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
072 7 |a MJCL  |2 thema 
245 1 0 |a Anticancer Drug Resistance  |h [electronic resource] :  |b Advances in Molecular and Clinical Research /  |c edited by Lori J. Goldstein, Robert F. Ozols. 
250 |a 1st ed. 1994. 
264 1 |a New York, NY :  |b Springer US :  |b Imprint: Springer,  |c 1994. 
300 |a XIII, 294 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Cancer Treatment and Research,  |x 0927-3042 ;  |v 73 
490 1 |a Springer eBook Collection 
505 0 |a 1. Genetics of Drug Resistance -- 2. P-Glycoprotein Homologues -- 3. Role of Protein Kinase C in Multidrug Resistance -- 4. Transcriptional Regulation of Multidrug Resistance Gene Expression -- 5. In vitro Models of Multidrug Resistance -- 6. In vivo Models of P-Glycoprotein-Mediated Multidrug Resistance -- 7. Molecular Diagnosis of Multidrug Resistance -- 8. Clinical Reversal of Multidrug Resistance -- 9. Role of Gene Amplification in Drug Resistance -- 10. Biochemical Modulation as an Approach to Reversal of Antimetabolite Resistance -- 11. Mechanisms of Acquired Resistance to Cisplatin -- 12. Mechanisms of Resistance to Alkylating Agents -- 13. Mechanisms of Resistance to Topoisomerase Inhibitors. 
520 |a Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these failures and continues to be an area of active investigation. Since the last volume in this series, we have learned that the energy-dependent drug efflux protein, p-glycoprotein, encoded by the MDR 1 gene, is a member of a family of structurally related transport polypeptides, thus allowing us to explore the relationship between structure and function. In addition to ongoing well designed clinical trials aimed at reversing MDR mediated drug resistance, the first gene therapy studies with the MDR 1 gene retrovirally transduced into human bone marrow cells are about to be initiated. Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance. It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells may overcome the cytotoxicity of our known chemotherapeutic agents. As our understanding of each of these mechanisms expands, well designed models will be necessary to test laboratory hypotheses and determine their relationship to drug resistance in humans. It is this integration of basic science and clinical investigation that will both advance our scientific knowledge and result in the improvement of cancer therapy. 
590 |a Loaded electronically. 
590 |a Electronic access restricted to members of the Holy Cross Community. 
650 0 |a Oncology  . 
650 0 |a Cancer research. 
650 0 |a Pharmacology. 
690 |a Electronic resources (E-books) 
700 1 |a Goldstein, Lori J.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Ozols, Robert F.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
830 0 |a Cancer Treatment and Research,  |x 0927-3042 ;  |v 73 
830 0 |a Springer eBook Collection. 
856 4 0 |u https://holycross.idm.oclc.org/login?auth=cas&url=https://doi.org/10.1007/978-1-4615-2632-2  |3 Click to view e-book  |t 0 
907 |a .b32110042  |b 04-18-22  |c 02-26-20 
998 |a he  |b 02-26-20  |c m  |d @   |e -  |f eng  |g xxu  |h 0  |i 1 
912 |a ZDB-2-SME 
912 |a ZDB-2-BAE 
950 |a Medicine (Springer-11650) 
902 |a springer purchased ebooks 
903 |a SEB-COLL 
945 |f  - -   |g 1  |h 0  |j  - -   |k  - -   |l he   |o -  |p $0.00  |q -  |r -  |s b   |t 38  |u 0  |v 0  |w 0  |x 0  |y .i21241697  |z 02-26-20 
999 f f |i b3b267bc-9345-599a-b9ba-3dc5cbee4ab0  |s 8b952166-6d2f-5729-ae9e-ec83b164c08d  |t 0 
952 f f |p Online  |a College of the Holy Cross  |b Main Campus  |c E-Resources  |d Online  |t 0  |e E-Book  |h Library of Congress classification  |i Elec File